Shares of ProMIS Neurosciences, Inc. (TSE:PMN – Get Free Report) traded down 3.8% on Monday . The company traded as low as C$5.98 and last traded at C$6.00. 19,701 shares traded hands during trading, an increase of 492% from the average session volume of 3,327 shares. The stock had previously closed at C$6.24.
ProMIS Neurosciences Price Performance
The company has a current ratio of 0.51, a quick ratio of 1.30 and a debt-to-equity ratio of 108.33. The company’s 50 day simple moving average is C$6.00. The stock has a market capitalization of C$51.48 million, a price-to-earnings ratio of -1.78 and a beta of 1.19.
ProMIS Neurosciences Company Profile
ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Recommended Stories
- Five stocks we like better than ProMIS Neurosciences
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- There Are Different Types of Stock To Invest In
- Williams-Sonoma Stock: Buy It and Never Let It Go
- What Investors Need to Know About Upcoming IPOs
- 5 Dividend ETFs to Buy and Hold Forever
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
